Revenio, a Finnish company and the global leader in tonometry, pioneered the non-contact rebound tonometer through its iCare product, which uses a magnetised probe to measure intraocular pressure without direct contact with the eye. As a result, the iCare device does not require anaesthesia or specialist training to operate. Newer models are also capable of measuring intraocular pressure in patients positioned supine.

In 2019, Revenio acquired the Italian company CentreVue, thereby expanding its capabilities beyond tonometry into broader diagnostic ophthalmology. CentreVue offers a competitive suite of fundus imaging devices for the monitoring of retinal diseases such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Its portfolio also includes microperimeters, which assess retinal sensitivity and structural changes.

Revenio derives approximately 50 per cent of its revenue from North America and 35 per cent from Europe.